Identification of a Novel Agnostic Predictive Multiomic Signature Via Elastic Net/Machine Learning in TALAPRO-2 ( TP-2), a Phase 3 Study of Talazoparib (TALA) Plus Enzalutamide (ENZA) Vs Placebo (PBO) Plus ENZA As First-Line (1L) Treatment in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)